Top

Published in:

Open Access 01-12-2018 | Research article

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site

Authors: Makoto Kodaira, Kan Yonemori, Tatsunori Shimoi, Akihiko Yoshida, Masayuki Yoshida, Atsuko Kitano, Akihiko Shimomura, Mayu Yunokawa, Chikako Shimizu, Yuichi Takiguchi, Yasuhiro Fujiwara, Kenji Tamura

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

The clinical utility and prognostic impact of presumed primary breast or ovarian cancer among patients with an unfavorable subset of cancer of unknown primary site (CUP) remains unclear. We aimed to evaluate the clinical relevance of the presumed primary site of CUP and the clinical outcome of site-specific therapy based on such presumptions.

Methods

Patients referred to our center who were diagnosed with unfavorable-subset CUP and treated between April 2007 and March 2015 were enrolled in this study. Data were collected retrospectively from the hospital database and electronic medical records. Presumptive primary breast or ovarian cancer was based on histological and immunohistochemical analyses and metastatic patterns. The outcomes of patients with unfavorable-subset CUP with a putative primary site in the breast or ovary (P-CUP) and of patients with unfavorable-subset CUP, but without P-CUP (U-CUP), were assessed.

Results

A total of 780 patients were referred to our hospital with malignancy of unknown origin. Of these, 409 patients were diagnosed with CUP and 344 patients with unfavorable-subset CUP. Following clinicopathological examination, 40 (11.6%) of the 344 patients had P-CUP and the remaining 303 (88.3%) patients had U-CUP. In total, 136 patients received chemotherapy (22 with P-CUP and 114 with U-CUP). Among the 22 patients with P-CUP, three received hormonal therapy for breast cancer, and 19 received chemotherapy based on the presumed primary organ (breast, 4; ovaries, 15). Conventional platinum-based chemotherapy was administered to 105 patients with U-CUP and non-platinum drug treatment to nine patients. The objective response rates were 61.1% (95% confidence interval [CI]: 38.6–83.6) and 41.1% (95% CI: 31.8–50.4) for patients with P-CUP and U-CUP, respectively. The median overall survival durations were 50.0 months and 16.9 months (log-rank: P = 0.002) for patients with P-CUP and U-CUP, respectively. P-CUP was identified as an independent predictor of good prognosis according to multivariate analysis.

Conclusions

Patients with P-CUP had higher response rates and a better prognosis compared with patients with U-CUP. It might thus be reasonable to classify this subset as a new category of CUP with a favorable prognosis.

Available only for authorised users

Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G, et al. Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):133–8.CrossRef

National Institute for Health and Care Excellence: Metastatic malignant disease of unknown primary origin in adults: diagnosis and management. Clinical guideline, 2010. nice.org.uk/guidance/cg104. Accessed 1 Oct 2016.

Ministry of Health, Labour and Welfare, Japan, Statistics and Information Department Minister's Secretariat: Vital statistics in 2011. http://www.mhlw.go.jp/english/database/db-hw/vs01.html Accessed 1 Oct 2016.

Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Cancer Treat Rev. 2009;35:570–3.CrossRefPubMed

Abbruzzese JL, Abbruzzese MC, Lenzi RJ, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995;13:2094–103.CrossRefPubMed

Riihimäki M, Thomsen H, Hemminki A, Sundquist K, Hemminki K. Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer. BMC Cancer. 2013;13:36.CrossRefPubMedPubMedCentral

Varadhachary GR, Raber MN. Carcinoma of unknown primary site. N Engl J Med. 2014;371:2040.CrossRefPubMed

Greco FA, Oien K, Erlander M, Osborne R, Varadhachary G, Bridgewater J, et al. Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes. Ann Oncol. 2012;23:298–304.CrossRefPubMed

Varadhachary GR, Spector Y, Abbruzzese JL, Rosenwald S, Wang H, Aharonov R. Prospective gene signature study using microRNA to identify the tis- sue of origin in patients with carcinoma of unknown primary. Clin Cancer Res. 2011;17:4063–70.CrossRefPubMed

10.

Greco FA, Lennington WJ, Spigel DR, Hainsworth JD. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst. 2013;105:782–90.CrossRefPubMed

11.

Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol. 2008;9:596–9.CrossRefPubMed

12.

Varadhachary GR, Karanth S, Qiao W, Carlson HR, Raber MN, Hainsworth JD, et al. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol. 2014;19:479–84.CrossRefPubMed

13.

Raghav K, Mhadgut H, McQuade JL, Lei X, Ross A, Matamoros A, et al. Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. PLoS One. 2016;2(11):e0154985.CrossRef

14.

Hainsworth JD, Wright EP, Johnson DH, Davis BW, Greco FA. Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining. J Clin Oncol. 1991;9:1931–8.CrossRefPubMed

15.

National Comprehensive Cancer Network: Clinical practice guidelines in oncology, occult primary (cancer of unknown primary [CUP]) version 1. 2017. https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf. Accessed 1 Oct 2016.

16.

Mazoujian G, Pinkus GS, Davis S, Haagensen DE Jr. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast: a marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol. 1983;110:105–12.PubMedPubMedCentral

17.

Ordonez NG, Awalt H, MacKay B. Mammary and extramammary Paget's disease: an immunohistochemical and ultrastructural study. Cancer. 1987;59:1173–83.CrossRefPubMed

18.

Wick MR, Lillemoe TJ, Copland GT, Swanson PE, Manivel JC, Kiang DT. Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin. Hum Pathol. 1989;20:281–7.CrossRefPubMed

19.

Huo L, Zhang J, Gilcrease MZ, Gong Y, Wu Y, Zhang H. Gross cystic disease fluid protein-15 and mammaglobin a expression determined by immunohistochemistry is of limited utility in triple-negative breast cancer. Histopathology. 2013;62:267–74.CrossRefPubMed

20.

Asch-Kendrick R, Cimino-Mathews A. The role of GATA3 in breast carcinomas: a review. Hum Pathol. 2016;48:37–47.CrossRefPubMed

21.

Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32:1566–71.CrossRefPubMed

22.

Laury AR, Hornick JL, Perets R, Krane JF, Corson J, Drapkin R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol. 2010;34:627–35.PubMed

23.

Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35:816–26.CrossRefPubMed

24.

Sangoi AR, Ohgami RS, Pai RK, Beck AH, McKenney JK, Pai RK. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. Mod Pathol. 2011;24:412–24.CrossRefPubMed

25.

Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor-1: a review. Appl Immunohistochem Mol Morphol. 2002;10:97–102.PubMed

26.

Kubba LA, McCluggage WG, Liu J, Malpica A, Euscher ED, Silva EG, et al. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol. 2008;21:485–90.CrossRefPubMed

27.

Yemelyanova A, Gown AM, Wu LS, Holmes BJ, Ronnett BM, Vang R. PAX8 expression in uterine adenocarcinomas and mesonephric proliferations. Int J Gynecol Pathol. 2014;33:492–9.CrossRefPubMed

28.

Al-Hussaini M, Stockman A, Foster H, McCluggage WG. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44:109–15.CrossRefPubMed

29.

Fadare O, James S, Desouki MM, Khabele D. Coordinate patterns of estrogen receptor, progesterone receptor, and Wilms tumor 1 expression in the histopathologic distinction of ovarian from endometrial serous adenocarcinomas. Ann Diagn Pathol. 2013;17:430–3.CrossRefPubMedPubMedCentral

30.

Hashimoto K, Sasajima Y, Ando M, Yonemori K, Hirakawa A, Furuta K, et al. Immunohistochemical profile for unknown primary adenocarcinoma. PLoS One. 2012;7:e31181.CrossRefPubMedPubMedCentral

31.

Greco FA, Spigel DR, Yardley DA, Erlander MG, Ma XJ, Hainsworth JD. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist. 2010;15:500–6.CrossRefPubMedPubMedCentral

32.

Varadhachary G. New strategies for carcinoma of unknown primary: the role of tissue-of-origin molecular profiling. Clinical cancer research. Clin Cancer Res. 2013;19:4027–33.CrossRefPubMed

33.

Ma X-J, Patel R, Wang X, Salunga R, Murage J, Desai R, et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med. 2006;130:465–73.PubMed

34.

Talantov D, Baden J, Jatkoe T, Hahn K, Yu J, Rajpurohit Y, et al. A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. J Mol Diagn. 2006;8:320–9.CrossRefPubMedPubMedCentral

35.

Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, et al. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol. 2008;26:4435–41.CrossRefPubMed

36.

Monzon FA, Lyons-Weiler M, Buturovic LJ, Rigl CT, Henner WD, Sciulli C, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol. 2009;27:2503–8.CrossRefPubMed

37.

Pentheroudakis G, Pavlidis N, Fountzilas G, Krikelis D, Goussia A, Stoyianni A, et al. Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary. Mol Cancer. 2013;12:57.CrossRefPubMedPubMedCentral

38.

Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013;31:217–23.CrossRefPubMed

39.

Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123–34.CrossRefPubMed

Title: Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site
Authors: Makoto Kodaira
Kan Yonemori
Tatsunori Shimoi
Akihiko Yoshida
Masayuki Yoshida
Atsuko Kitano
Akihiko Shimomura
Mayu Yunokawa
Chikako Shimizu
Yuichi Takiguchi
Yasuhiro Fujiwara
Kenji Tamura
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-4092-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma

The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors

EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer

Dynamic Hyaluronan drives liver endothelial cells towards angiogenesis

Impact of breast cancer on prospective memory functioning assessed by virtual reality and influence of sleep quality and hormonal therapy: PROSOM-K study

The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer